Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Tumor Lysis Syndrome 1Hematologic Neoplasms 1

Interventions

Dexamethasone 13Bevacizumab 9Saline Solution 8Bupivacaine 8Tobacco Use Cessation Devices 7Specimen Handling 7Nivolumab 7Magnetic Resonance Spectroscopy 7Lenalidomide 7Fluorouracil 7pembrolizumab 6Rituximab 6Prednisone 6Letrozole 6Cisplatin 6Carboplatin 6Sodium Chloride 5Ropivacaine 5Propofol 5Human Papillomavirus Recombinant Vaccine nonavalent 5trametinib 4lenvatinib 4dabrafenib 4cabozantinib 4anlotinib 4Trastuzumab 4Tamoxifen 4Standard of Care 4Paclitaxel 4Immune Checkpoint Inhibitors 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Uric Acid × 1 year × Clear all
NCT04745910 2026-05-06

Pegloticase for the Reduction of Uric Acid in Patients With Tumor Lysis Syndrome

M.D. Anderson Cancer Center

Phase 4 Completed
10 enrolled
Other hematologic neoplasm

Tumor Lysis Syndrome, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡